Company: ARWR
Filing Date: 2025-01-29
Form Type: ARS
Source: 0001628280-25-002866
Chunk: 171

Company: ARROWHEAD PHARMACEUTICALS, INC.
Filing Date: 2025-01-29
Form: ARS
Chunk 171
---
 the director serves are as follows: Board of Directors: 2023 Annual Retainer: 2024 Annual Retainer: All non-employee directors $80,000 $80,000 Additional retainer for Non-Executive Chairman of the Board $15,000 $15,000 Audit Committee: Chairman $5,000 $5,000 Compensation Committee: Chairman $5,000 $5,000 The following table sets forth the total compensation paid to our non-employee directors in fiscal 2024. Dr. Anzalone’s compensation is set forth in the discussion of Executive Compensation and in the Summary Compensation Table. Name Fee Earned or Paid in Cash ($) Stock Awards ($) (1) (2) Total ($) Douglass Given (3) $95,000 $380,833 $475,833 Michael S. Perry $80,000 $380,833 $460,833 Mauro Ferrari $80,000 $380,833 $460,833 William Waddill $90,000 $380,833 $470,833 Hongbo Lu (4)(5) $43,333 $761,666 $804,999 Adeoye Olukotun $80,000 $380,833 $460,833 Victoria Vakiener $80,000 $380,833 $460,833 (1) This column represents the total grant date fair value, computed in accordance with ASC 718, of RSUs granted during fiscal year 2024 to each director. The assumptions used to calculate the value of the stock underlying the RSU awards are set forth in Note 9 of the Notes to the Consolidated Financial Statements included with the Company’s Annual Report on Form 10-K. (2) The RSUs granted to non-employee directors vest one year from the date of grant, subject to continued service through the vesting date, with the exception of the RSUs granted to Dr. Lu in connection with her appointment to the Board, which vest in three equal installments on each anniversary of the date of grant , subject to continued service through each such vesting date. (3) Douglass Given retired from the Board effective as of December 31, 2024. (4) Dr. Lu joined the Board during fiscal year 2024 and her cash compensation was pro-rated for such fiscal year. (5) In connection with her appointment, Dr. Lu received a sign-on grant of restricted stock units valued at $761,666. As of the last day of fiscal year 2024, the